炎症性肠病患者QuantiFERON-TB Gold In-Tube试验结果不确定的相关因素
该病例对照研究纳入2011至2013年某三级转诊中心400例接受QFT-GIT检测的炎症性肠病患者,比较结果不确定与确定患者的特征。11.5%的患者结果不确定,多因素分析显示使用全身皮质类固醇和血清白蛋白低于3.5 g/dL与结果不确定风险增加独立相关。
要点
- 炎症性肠病患者QFT-GIT结果不确定率为11.5%。
- 使用全身皮质类固醇者结果不确定的比值比为2.92(95%CI 1.44-5.88)。
- 血清白蛋白低于3.5 g/dL者结果不确定的比值比为3.62(95%CI 1.36-9.60)。
核心结论
- 在炎症性肠病患者中,全身皮质类固醇治疗和低白蛋白水平与QFT-GIT结果不确定的可能性增加相关。
研究设计与样本
- 病例对照研究,纳入2011至2013年某三级转诊中心400例有QFT-GIT检测结果且诊断为炎症性肠病的成年患者,其中克罗恩病265例、溃疡性结肠炎135例。
主要发现
- QFT-GIT结果不确定者占11.5%。
- 结果不确定组与结果确定组相比,使用全身皮质类固醇者比例为60.9% vs 30.5%(P < .001)。
- 结果不确定组与结果确定组相比,C反应蛋白高于0.8 mg者比例为62.2% vs 39.9%(P = .005)。
- 结果不确定组与结果确定组相比,红细胞沉降率高于15 mm/h者比例为55.6% vs 35.8%(P = .01)。
- 结果不确定组与结果确定组相比,血清白蛋白低于3.5 g/dL者比例为33.3% vs 6.3%(P < .001),低血红蛋白者比例为52.2% vs 28.3%(P = .001)。
关键数值与推荐
- 多因素分析中,使用皮质类固醇与QFT-GIT结果不确定风险增加独立相关(校正OR 2.92;95%CI 1.44-5.88;P = .003)。
- 多因素分析中,血清白蛋白低于3.5 g/dL与QFT-GIT结果不确定风险增加独立相关(校正OR 3.62;95%CI 1.36-9.60;P = .009)。
- 未发现皮质类固醇治疗与QFT-GIT结果不确定比值比之间存在剂量相关效应。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: The QuantiFERON-Tuberculosis Gold In-Tube (QFT-GIT) (QIAGEN Group, Hilden, Germany) test is widely used to screen for latent Mycobacterium tuberculosis infection in patients with inflammatory bowel diseases (IBD) before treatment with a tumor necrosis factor antagonist. The test frequently produces indeterminate results, prompting additional testing. We evaluated factors associated with indeterminate results from the QFT-GIT test among patients with IBD. METHODS: We conducted a case-control study among eligible adults with QFT-GIT test results and a concomitant diagnosis of IBD receiving care at a tertiary referral center from 2011 through 2013. We compared patients with IBD with indeterminate and determinate (positive or negative) results from the QFT-GIT test. We collected data on patient demographics, clinical features, laboratory parameters, and medication use from medical charts. We calculated odds ratios (OR) and 95% CIs using multivariate logistic regression models. RESULTS: A total of 400 patients with IBD (265 Crohn's disease and 135 ulcerative colitis) were included in the final analyses. Indeterminate results were noted in 11.5% of patients. At the time of testing, a higher proportion of patients with indeterminate results from the QFT-GIT test were on systemic corticosteroid therapy (60.9% vs 30.5% of patients with conclusive test results; P < .001), had levels of C-reactive protein above 0.8 mg (62.2% vs 39.9% of patients with clear test results; P = .005), had an erythrocyte sedimentation rate above 15 mm/h (55.6% vs 35.8% of patients with clear test results; P = .01), had serum levels of albumin below 3.5 g/dL (33.3% vs 6.3% of patients with clear test results; P < .001), and had low levels of hemoglobin (52.2% vs 28.3% of patients with clear test results; P = .001). In multivariable analysis, corticosteroid use (adjusted OR, 2.92; 95% CI, 1.44-5.88; P = .003) and serum levels of albumin below 3.5 g/dL (adjusted OR, 3.62; 95% CI, 1.36-9.60; P = .009) were independently associated with increased risk of indeterminate QFT-GIT test results. We did not identify a dose-related effect with corticosteroid therapy and the odds of indeterminate QFT-GIT test results. CONCLUSIONS: In a case-control study of patients with IBD, we associated systemic corticosteroid therapy and low levels of albumin with an increased likelihood of having indeterminate QFT-GIT test result.
引用
- Kaur M, Singapura P, Kalakota N, et al. Factors That Contribute to Indeterminate Results From the QuantiFERON-TB Gold In-Tube Test in Patients With Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2017. PMID: 29175527. doi:10.1016/j.cgh.2017.11.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。